NCT05833386 Effect of Preoperative Silodosin on Feasibility of Ureteral Access Sheath Insertion
| NCT ID | NCT05833386 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Al-Azhar University |
| Condition | Renal Stone |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,000 participants in total. It began in 2022-10-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ureteral access sheath (UAS) is an ancillary device widely used by urologists to facilitate fast, repeatable, and safe access to ureters and collecting systems; improve visibility; reduce the risk of infection by reducing intrarenal pressure; and protect ureters and scopes when extracting multiple stones during surgery. Insertion of ureteric access sheath may be difficult due to tight ureter, so sometimes preoperative stenting might be needed. Silodosin is an α1A adrenoceptor with high affinity and selectivity for the ureteric muscle, which may reduce ureteral spasm. Oral a1-blockers can reduce intraureteral pressure, and may reduce maximal ureteral access sheath insertion force.¹ Preoperative silodosin protects against significant ureteral injury related to UAS insertion during fURS and decreases postoperative pain level. Silodosin premedication might be an effective and safe technique to replace prestenting.²
Eligibility Criteria
Inclusion Criteria: * All patients with renal stones who will undergo flexible ureteroscopy and planned for using ureteral access sheath Exclusion Criteria: * Paediatric age group (less than 18 year)
Frequently Asked Questions
Who can join the NCT05833386 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Stone. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05833386 currently recruiting?
Yes, NCT05833386 is actively recruiting participants. Visit ClinicalTrials.gov or contact Al-Azhar University to inquire about joining.
Where is the NCT05833386 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT05833386 clinical trial?
NCT05833386 is sponsored by Al-Azhar University. The trial plans to enroll 2,000 participants.